|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
US6077851A
(en)
*
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6395750B1
(en)
|
1999-10-25 |
2002-05-28 |
Active Biotech Ab |
Drugs for the treatment of malignant tumors
|
|
EP1365794A2
(en)
|
2000-07-21 |
2003-12-03 |
Lue, Tom |
Prevention and treatment of sexual arousal disorders
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
US7153968B2
(en)
*
|
2002-06-25 |
2006-12-26 |
Merck Frosst Canada, Ltd. |
8-(biaryl)quinoline PDE4 inhibitors
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
WO2005000244A2
(en)
|
2003-06-25 |
2005-01-06 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
EP1763361A2
(en)
|
2004-04-01 |
2007-03-21 |
Elan Pharmaceuticals, Inc. |
Steroid sparing agents and their use
|
|
EP1796710A4
(en)
|
2004-09-02 |
2010-05-26 |
Teva Pharma |
THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
|
|
PL1797109T3
(pl)
|
2004-09-09 |
2016-11-30 |
|
Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
|
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
AU2006204699B2
(en)
|
2005-01-13 |
2012-04-26 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
|
PL1902034T3
(pl)
|
2005-06-02 |
2011-09-30 |
Glenmark Pharmaceuticals Sa |
Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
CN107176923A
(zh)
|
2005-10-19 |
2017-09-19 |
泰华制药工业有限公司 |
拉奎尼莫钠晶体及其制备方法
|
|
ATE534630T1
(de)
|
2005-10-26 |
2011-12-15 |
Merck Serono Sa |
Sulfonamidderivate und deren verwendung zur modulation von metalloproteinasen
|
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
|
WO2007100770A2
(en)
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
US8410115B2
(en)
*
|
2006-02-28 |
2013-04-02 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
RS20080391A
(sr)
|
2006-03-03 |
2009-07-15 |
Elan Pharmaceuticals Inc., |
Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
|
|
KR20080112300A
(ko)
|
2006-03-16 |
2008-12-24 |
제넨테크, 인크. |
Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
KR101495327B1
(ko)
|
2006-06-12 |
2015-02-24 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 라퀴니모드 제제
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
WO2008009407A2
(en)
|
2006-07-17 |
2008-01-24 |
Novartis Ag |
Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
|
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
|
EP2056807B1
(en)
|
2006-08-17 |
2012-09-26 |
University Of Chicago |
Treatment of inflammatory diseases
|
|
US20100136125A1
(en)
|
2006-12-28 |
2010-06-03 |
Jacobus Pharmaceutical Company, Inc. |
Method of treating inflammatory bowel disease
|
|
CA2970273C
(en)
|
2007-07-11 |
2020-04-14 |
Medicinova, Inc. |
Treatment of progressive neurodegenerative disease with ibudilast
|
|
US20100260716A1
(en)
|
2007-10-23 |
2010-10-14 |
Ucb Pharma Gmbh |
Compounds for treating demyelination conditions
|
|
US8178127B2
(en)
|
2007-12-20 |
2012-05-15 |
Teva Pharmaceuticals Industries, Ltd. |
Stable laquinimod preparations
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
CA2736091A1
(en)
|
2008-09-03 |
2010-03-11 |
Teva Pharmaceutical Industries Ltd. |
2-oxo-1,2-dihydro-quinoline modulators of immune function
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
HUE026406T2
(en)
|
2009-06-19 |
2016-06-28 |
Teva Pharma |
Treatment of multiple sclerosis with laquinimod
|
|
CN105616410A
(zh)
*
|
2009-07-30 |
2016-06-01 |
泰华制药工业有限公司 |
利用拉喹莫德治疗克隆氏病
|
|
ES2731052T3
(es)
|
2009-08-10 |
2019-11-13 |
Active Biotech Ab |
Tratamiento de la enfermedad de Huntington usando laquinimod
|
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
|
KR20150135552A
(ko)
|
2010-03-03 |
2015-12-02 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드를 이용한 루푸스 신장염의 치료
|
|
SG183515A1
(en)
|
2010-03-03 |
2012-10-30 |
Teva Pharma |
Treatment of lupus arthritis using laquinimod
|
|
WO2011109531A1
(en)
|
2010-03-03 |
2011-09-09 |
Teva Pharmaceutical Industries Ltd. |
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
|
|
BR112013000607A2
(pt)
|
2010-07-09 |
2016-06-28 |
Teva Pharma |
5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
|
|
JP2013535437A
(ja)
|
2010-07-09 |
2013-09-12 |
テバ ファーマシューティカル インダストリーズ リミティド |
重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
|
|
JP2013544887A
(ja)
|
2010-12-07 |
2013-12-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用
|
|
JP5767393B2
(ja)
|
2011-03-31 |
2015-08-19 |
ファイザー・インク |
新規二環式ピリジノン
|
|
US20130029916A1
(en)
|
2011-07-28 |
2013-01-31 |
Yossi Gilgun |
Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
|
|
CN103781355A
(zh)
|
2011-07-28 |
2014-05-07 |
泰华制药工业有限公司 |
用拉喹莫德与干扰素-β的组合治疗多发性硬化症
|
|
SG11201401330YA
(en)
|
2011-10-12 |
2014-05-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
|
|
AR090073A1
(es)
|
2012-02-16 |
2014-10-15 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
US20140107154A1
(en)
|
2012-10-12 |
2014-04-17 |
Teva Pharmaceutical Industries, Ltd. |
Laquinimod for reducing thalamic damage in multiple sclerosis
|
|
CA2890194A1
(en)
|
2012-11-07 |
2014-05-15 |
Teva Pharmaceutical Industries Ltd. |
Amine salts of laquinimod
|
|
EP2956137A4
(en)
|
2013-02-15 |
2016-08-03 |
Teva Pharma |
TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
|
|
HK1220125A1
(zh)
|
2013-03-14 |
2017-04-28 |
Teva Pharmaceutical Industries Ltd. |
拉喹莫德的透皮配方
|
|
WO2014153145A2
(en)
|
2013-03-14 |
2014-09-25 |
Teva Pharmaceutical Industries Ltd. |
Crystals of laquinimod sodium and improved process for the manufacture thereof
|
|
WO2015109083A1
(en)
*
|
2014-01-17 |
2015-07-23 |
Teva Pharmaceutical Industries Ltd. |
Treatment of crohn's disease using low doses of laquinimod
|